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Diabetic patients are at increased risk of developing coronary artery disease and experience worse clinical 
outcomes following acute myocardial infarction. Novel therapeutic strategies are required to protect the 
myocardium against the effects of acute ischaemia–reperfusion injury (IRI). These include one or more brief 
cycles of nonlethal  ischaemia and reperfusion prior to the ischaemic event (ischaemic preconditioning 
[IPC]) or at the onset of reperfusion (ischaemic postconditioning [IPost]) either to the heart or to 
extracardiac organs (remote ischaemic conditioning [RIC]). Studies suggest that the diabetic heart is 
resistant to cardioprotective strategies, although clinical evidence is lacking. We overview the available 
animal models of diabetes, investigating acute myocardial IRI and cardioprotection, experiments 
investigating the effects of hyperglycaemia on susceptibility to acute myocardial IRI, the response of the 
diabetic heart to cardioprotective strategies e.g. IPC, IPost and RI. Finally highlighting the effects of anti-
hyperglycaemic agents on susceptibility to  acute myocardial IRI and cardioprotection. 
 
1 | INTRODUCTION 
Diabetes mellitus (DM) affects 430 million adults globally (8.8% of the world's population) and is a major 
cause of morbidity and mortality. The major pathological consequences of diabetes mellitus arise from the 
effects of chronic hyperglycaemia on the macrovasculature (resulting in coronary artery disease, peripheral 
artery disease and cerebrovascular disease) and microvasculature (resulting in diabetic retinopathy, 
nephropathy and neuropathy). In diabetes mellitus patients, the risk of developing cardiovascular disease is 
increased twofold to fourfold, when compared with non-diabetes mellitus patients (Bertoluci & Rocha, 
2017). Furthermore, patients with experience worse clinical outcomes in a number of clinical settings of 
acute myocardial ischaemia–reperfusion injury (IRI), including acute myocardial infarction (AMI; Donahoe 
et al., 2007), coronary angioplasty (Mathew et al., 2004) and cardiac bypass surgery (Alserius, Hammar, 
Nordqvist, & Ivert, 2006), suggesting that the diabetic heart may be more susceptible to acute ischaemia–
reperfusion injury. In contrast, animal studies have been inconclusive with experimental studies suggesting 
that the diabetic heart may be more, equally, or even less susceptible to acute ischaemia–reperfusion 
injury (Whittington et al., 2013). However, one major reason for the disparity between the clinical and 
animal data may be due to the choice of acute myocardial ischaemia–reperfusion injury models and 
diabetic animal models used in the experimental studies (Whittington et al., 2013). Indeed, standardisation, 
reproducibility and rigour are mandatory in animal and clinical studies to achieve clinical translation in 
cardioprotection (Bøtker et al., 2018; Jones et al., 2015). 
Given the worse clinical outcomes in diabetic patients with coronary artery disease, novel therapeutic 
strategies, which are effective in the diabetic heart, are required to protect the myocardium against the 
detrimental effects of acute ischaemia–reperfusion injury. A number of strategies exist for protecting the 
heart against acute. These are based on applying one or more brief cycles of non-lethal ischaemia and 
reperfusion prior to the index ischaemic event (ischaemic preconditioning [IPC]) or at the onset of 
reperfusion (ischaemic postconditioning [IPost]) either to the heart itself or to an organ/tissue F1 away 
from the heart (remote ischaemic conditioning [RIC]; Figure 1). The latter has relevant therapeutic potential 
in the clinical scenario (Pickard et al., 2015). In order to translate ischaemic conditioning into the clinical 
arena for the benefit of diabetic patients, it is important to first determine in animal studies whether the 
diabetic heart is amenable to endogenous cardioprotection. In experimental animal studies, it appears that 
the diabetic heart is resistant to endogenous cardioprotection (Ferdinandy, Hausenloy, Heusch, Baxter, & 
Schulz, 2014), but clinical evidence for this is lacking. Pharmacological agents, which recruit the signalling 
pathways underlying ischaemic conditioning, can recapitulate cardioprotection—termed “pharmacological 
conditioning.” Interestingly, by targeting these signalling pathways, many anti-diabetic agents can either 
mimic or confound cardioprotection, further complicating the study of cardioprotection in the diabetic 
heart. 
In this article, firstly, we provide an overview of the commonly used rodent and pig models of diabetes for 
investigating acute myocardial ischaemia–reperfusion injury and cardioprotection. Next, we perform a 
comprehensive review of experimental studies investigating the effects of hyperglycaemia on susceptibility 
to acute myocardial ischaemia–reperfusion injury. Then, we review the response of the diabetic heart to 
cardioprotective strategies such as IPC, IPost and RIC. Finally, we highlight the effects of anti-
hyperglycaemic agents on susceptibility to acute myocardial ischaemia–reperfusion injury and 
cardioprotection. 
 
2 | EXPERIMENTAL ANIMAL MODELS OF 
DIABETES 
Animal models of diabetes mellitus are crucial to understanding the pathophysiological effects of diabetes on the cardiovascular system, 
identifying and validating novel therapeutic targets and signalling pathways. Diabetes mellitus animal models can be subdivided into 
four groups: surgical, pharmacological, diet and genetic/selective inbreeding-induced diabetes mellitus (summarised in Table 1). Surgical 
(pancreatectomy) and pharmacological models usually result in pancreatic mass reduction, insulin deficiency and hyperglycaemia and 
thus represent type 1 diabetes mellitus (T1DM) models. Pharmacological models include injection of drugs such as streptozotocin or 
alloxan, which are selectively toxic to pancreatic β-cells, and induce diabetes mellitus as early as 24–48 hr post-injection (Rerup & 
Tarding, 1969). Selective in-breeding has produced several rodent models of type 2 diabetes mellitus (T2DM), usually associated with a 
panoply of risk factors. The most common genetic rodent models of type 2 diabetes mellitus include Zucker diabetic fatty, obese ZSF1 
rats, and db/db and ob/ob mice. All of these models display dysfunctional or absent leptin homeostasis and insulin resistance at 
different time points. Type 2 diabetes mellitus can also be induced by diets with high-fat and/or high-carbohydrate content (Table 1; 
Maioli et al., 2016). Diet-induced diabetes mellitus requires months to achieve the full type 2 diabetes mellitus spectrum and no standard 
protocol has been established. This prolonged onset of type 2 diabetes mellitus might be closer to the human scenario, providing 
several opportunities to perform acute myocardial ischaemia–reperfusion injury studies according to the stage of the disease. Variations 
in diet compositions are particularly important considering the vast amount of studies reporting that the type of fat in the diet can affect 
cardioprotection or pathology (Stanley, Dabkowski, Ribeiro, & O'Connell, 2012). Thus, diet formulation should be taken into account 
(Heydemann, 2016). Many of these rodent models share many features with human diabetes mellitus cardiomyopathy (Bugger & Abel, 
2008) as well as higher incidence of acute myocardial ischaemia–reperfusion injury (Greer, Ware, & Lefer, 2006). There are several 
limitations of diabetes mellitus animal models that need to be taken into consideration: (a) rodent models present with sudden and 
uncontrolled hyperglycaemia or insulin resistance, while in the clinical setting, the onset of diabetes is often gradual and the 
hyperglycaemia is usually well controlled with anti-diabetic medication; (b) pancreatic islets architecture is distinct from humans; (c) 
monogenic models are not representative of human diabetes mellitus; (d) diabetes mellitus develops at varying stages in rodent models, 
which has an impact on the timing of the acute myocardial ischaemia–reperfusion injury study. In the initial stages, ischaemia– 
reperfusion injury may reflect changes that are secondary to damaging circulatory metabolic milieu and the underlying obesity and 
insulin resistance, whereas in the later stages, ischaemia–reperfusion injury may reflect the added effects of hyperglycaemia of different 
durations and (e) in genetic models, metabolic dysregulation appears at very early developmental stages. Finally, the lack of 
spontaneous ischaemia and atherosclerosis in rodents (Boudina & Abel, 2007) could be considered either a disadvantage or an 
advantage since the impact of obesity, insulin resistance and diabetes can be studied independently of coronary artery disease 
(Ishibashi, Goldstein, Brown, Herz, & Burns, 1994). 
Although there is no animal model that fully represents the human pathology of diabetes, large animal models are available that closely 
mimic human cardiac physiology and anatomy. In particular, the minipig and pig heart models with regional myocardial ischaemia–
reperfusion injury is of paramount translational value (reviewed in Elmadhun et al., 2013). Pig models of diet-induced metabolic 
syndrome and type 2 diabetes mellitus, streptozocin- or alloxan-induced type 1 diabetes mellitus or genetically engineered pigs can be 
used in ischaemia–reperfusion injury studies (Diemar et al., 2015; Jones et al., 2015). Although the cardioprotective signalling is in part 
different from that in rodent hearts, all cardioprotective phenomena described above have been demonstrated in pigs (Skyschally et al., 
2018). 
 
3 | EFFECTS OF HYPERGLYCAEMIA AND DIABETES ON INFARCT SIZE 
In clinical studies, perturbations of blood glucose levels at the time of acute myocardial ischaemia–reperfusion injury, either 
hyperglycaemia or hypoglycaemia, are known to be associated with poor cardiovascular outcomes. This observation was supported in 
one of the largest epidemiological studies of its type, the Cooperative Cardiovascular Project (Kosiborod et al., 2005). This retrospective 
study of 141,680 patients found that hyperglycaemia was deleterious in diabetic patients and particularly in those without recognised 
diabetes. In fact, clinical outcomes in non-diabetic patients were significantly worse when compared with diabetic individuals, with a 
markedly steeper relationship between presentation glucose levels and 30-day and 1-year mortality (Kosiborod et al., 2005). As 
summarised elsewhere, this has been observed in a number of clinical studies (Deedwania et al., 2008), but the challenge has been to 
demonstrate causality between hyperglycaemia and clinical outcomes. Interestingly, myocardial infarct (MI) size, as quantified by late 
gadolinium enhancement cardiovascular magnetic resonance, correlated with glucose levels at the time of presentation, with greater 
infarct sizes (ISs) observed in non-diabetic than in diabetic patients presenting with similar blood glucose levels (Eitel et al., 2012). In 
addition to glucose levels, insulin resistance and altered metabolism are important in determining the cardiac damaging effects of 
diabetes (Giblett, Clarke, Dutka, & Hoole, 2016; Ishibashi et al., 1994). In order to better understand the relationship between glucose 
levels and MI size in the experimental setting, we undertook a literature search in PubMed using the terms “diabetes, hyperglycaemia, 
ischemia-reperfusion injury, infarct size and heart” of studies published between January 2012 and February 2019. From the obtained 
512 articles, we identified 84 original articles that reported on infarct size for both control and hyperglycaemic or diabetic hearts. For 
studies older than 2012, we made use of articles analysed by a previous review article on this topic (Miki, Itoh, Sunaga, & Miura, 2012)—
this provided another 46 articles. Figure 2 provides a summary of these 130 articles, which have been classified into acute 
hyperglycaemic conditions, early phase (≤2 weeks) of type 1 diabetes mellitus, late phase of type 1 diabetes mellitus (>2 weeks) and 
type 2 diabetes mellitus. Each condition was additionally split into ex vivo (isolated heart) and in vivo models. This allowed us to separate 
pathological effects of glucose that could be attributed to the heart itself (intrinsic properties) or to changes in the metabolic milieu of 
the circulatory system and the heart. 
 
3.1 | Acute hyperglycaemia 
In the isolated heart perfused in the absence of insulin, most studies reported increased infarct size with hyperglycaemia, although some 
studies also reported decreased infarct size (Figure 2a). Increased infarct size was commonly observed with glucose levels >30 mM, 
whereas reduced infarct size was associated with glucose around 8 mM; infarct size was unaltered with glucose levels between 11 and 22 
mM. In the in vivo models (Figure 2b), most studies compared normoglycaemia, 5–10 mM, with hyperglycaemic levels between 15 and 
20 mM demonstrating, for unclear reasons, either no effects on infarct  size or increased vulnerability to acute ischaemia–reperfusion 
injury. It therefore seems that at 20-mM glucose, in vivo hearts show vulnerability to acute ischaemia–reperfusion injury as compared 
with ex vivo hearts. This seems counterintuitive knowing that, in vivo, hyperglycaemia increases insulin plasma level, whereby insulin can 
act as a cardioprotective agent against acute ischaemia–reperfusion injury (Zuurbier, Eerbeek, & Meijer, 2005) through activation the 
Akt/hexokinase II (HKII) pathway. This could be explained by the fact that hyperglycaemia directly impairs insulin signalling (Yu et al., 
2014). Although for most in vivo studies only hyperglycaemic conditions of 15–20 mM were examined, one study showed that infarct 
size increased when raising glucose from 16 to 30 mM (Kersten, Schmeling, Orth, Pagel, & Warltier, 1998). For both the ex vivo and in 
vivo conditions, hyperglycaemia above 10 mM never reduced infarct size of the heart. In summary, acute hyperglycaemia increases 
infarct size in the isolated heart when glucose >30 mM, whereas increases in infarct size are already present in vivo at glucose levels of 
20 mM. 
 
3.2 | Early phase of type 1 diabetes mellitus (≤2 weeks) 
 
Interestingly, the early phase of type 1 diabetes mellitus is often associated with reduced infarct size in the ex vivo heart (Figure 2c). 
However, it should be noted that in all these isolated heart studies, the hearts were actually perfused at normoglycaemia (5–11 mM), 
which deviates from their hyperglycaemic metabolic milieu in vivo. Various mechanisms explaining this intrinsic protected state of early 
type 1 diabetes mellitus heart have been proposed, such as increased expression and/or phosphorylation of Akt, endothelial NOS 
(eNOS), PKC, ERK and heat shock proteins or maintenance of end-ischaemic mitochondrial hexokinase II (HKII; Gurel et al., 2013). 
Keeping HKII at the mitochondria during ischaemia is known to confer protection against cardiac ischaemia–reperfusion injury (Smeele 
et al., 2011). In contrast, in vivo, the early phase of type 1 diabetes mellitus was associated with an increase in susceptibility to acute 
ischaemia–reperfusion injury (Figure 2d). This is likely due to the fact that in the in vivo setting, hearts are subjected to acute ischaemia–
reperfusion injury at higher glucose levels >20 mM. In summary, in the early type 1 diabetes mellitus condition, there appears to be 
intrinsic protection in the isolated heart, whereas there is increased vulnerability of the in vivo heart to acute ischaemia–reperfusion 
injury and this is likely due to the hyperglycaemic conditions. This offers the therapeutic option of targeting these extracardiac factors of 
the metabolic milieu, for example, with exogenous insulin and drugs that lower blood glucose, to reduce acute ischaemia–reperfusion 
injury of the early type 1 diabetes mellitus heart. 
 
3.3 | Late phase of type 1 diabetes mellitus (>2 weeks) 
After prolonged type 1 diabetes mellitus, the isolated heart appears to lose its protected state, showing either similar or increased infarct 
size (Figure 2e). It is unknown why protection is lost—this may be due to chronic low insulin signalling, prolonged hyperglycaemia, 
and/or dyslipidaemia. In in vivo condition (Figure 2f), the susceptibility to acute ischaemia–reperfusion injury was also increased. 
 
3.4 | Type 2 diabetes mellitus 
The isolated heart of type 2 diabetes mellitus animals shows a mixed response to acute ischaemia–reperfusion injury experiments 
performed using the isolated heart of type 2 diabetes mellitus animals that show mixed results, with most studies reporting either 
increased infarct size or no change in infarct size (Figure 2g) and a minority showing reduced infarct size. However, type 2 diabetes 
mellitus in the in vivo setting was mainly associated with increased infarct size (Figure 2h), probably due to the fact that all the isolated 
hearts were perfused with normal (5–7 mM) levels of glucose, whereas in vivo hearts are subjected to much higher glucose (>20 mM) 
and free fatty acid levels. These hearts are insulin resistant, rendering the protective reperfusion injury salvage kinase (RISK) pathway to 
be less responsive to acute ischaemia–reperfusion injury. The RISK pathway concerns pro-survival kinase signalling cascades, such as 
PI3K–Akt and p42/p44 ERK Erk 1/2. Activation of these kinase pathways confers protection against ischaemia–reperfusion injury 
(Hausenloy & Yellon, 2004). 
Interestingly, in the in vivo setting, a few studies report hearts to have reduced infarct size. This could be related to the obesity paradox 
and early type 2 diabetes mellitus, where insulin signalling may be still effective and cellular protective signalling pathways are initially 
activated, similar to that observed in the early type 1 diabetes mellitus setting.  
In summary, it appears that hyperglycaemia and diabetes increase the susceptibility to acute myocardial ischaemia–reperfusion injury 
and observed differences arise due to the ischaemia–reperfusion injury models used and the duration of diabetes. 
 
4 | EFFECTS OF HYPERGLYCAEMIA AND DIABETES ON ISCHAEMIC PRECONDITIONING (IPC) 
In order to protect the diabetic heart against the detrimental effects of acute ischaemia–reperfusion injury, it is important to ascertain 
whether the diabetic heart is amenable to cardioprotective strategies such as IPC, IPost and RIC. Here, we review the effects of 
hyperglycaemia and diabetes on cardioprotection elicited by IPC. The potent infarct size-limiting effects of IPC have been confirmed in 
all species tested including man and have also been shown to be effective in the multicentre network of experimental research centres 
that made up the Consortium for preclinicAl assESsment of cARdioprotective therapies (Jones et al., 2015). However, there is substantial 
experimental evidence that the infarct-limiting effects of IPC are attenuated in the presence of co-morbidities including diabetes mellitus 
(Ferdinandy et al., 2014). IPC cardioprotective mechanisms have been extensively described and include RISK, survivor activating factor 
enhancement (SAFE), and NO/PKG pathways that converge on mitochondria (Hausenloy et al., 2016; Penna et al., 2015). 
Several studies have evaluated the effect of IPC on cardiac ischaemia–reperfusion injury in animal models of diabetes. A reduced 
cardioprotective effect of IPC has been reported in many studies (Ebel et al., 2003; Kersten et al., 1998). No effects or worsening of acute 
ischaemia–reperfusion injury have also been reported as a consequence of either IPC or pharmacological preconditioning (del Valle, 
Lascano, Negroni, & Crottogini, 2003; Kristiansen et al., 2004). Recent representative examples of ischaemic and pharmacological 
preconditioning studies are summarised in Table 2. It appears that hyperglycaemia per se is responsible for the attenuation of the 
protective efficacy of IPC. Indeed, acute hyperglycaemia may blunt infarct size reduction by IPC, as well as the protection induced by 
mitochondrial KATP channel opener and anaesthetics (Kehl et al., 2002; Kersten et al., 1998). The blunting may be overcome by increasing 
the dose of protectants or the numbers/duration of PC cycles. Indeed, in animal models, several authors (Hausenloy, Wynne, Mocanu, & 
Yellon, 2013; Tsang, Hausenloy, Mocanu, Carr, & Yellon, 2005) reported that cardioprotection by IPC against ischaemic injury requires an 
increased preconditioning stimulus in diabetic hearts. This finding was confirmed by Hjortbak et al. (2018) who reported that a strong 
IPC stimulus may protect diabetic heart in prediabetic and early- and late-stage type 2 diabetes mellitus in a Zucker diabetic fatty rat 
model. Drugs that affect glycaemia or improve the cardioprotective pathways may restore IPC cardioprotection (see Table 2). Yet studies 
emphasise that hypoglycaemia and glucose fluctuations, obtained with insulin or sulphonylureas, can aggravate the cardiac susceptibility 
to acute ischaemia–reperfusion injury and the response to cardioprotective manoeuvres to a greater extent in a non-diabetic when 
compared with a diabetic model (Pælestik et al., 2017; Saito et al., 2016; see also later section on the effects of anti-hyperglycaemic 
medications).  
Contradictory results observed in animal models have also been reported in patients with diabetes, where the picture is complicated by 
the large interindividual variability of the methods used to assess infarct size, so that a large number of patients is necessary to define 
the efficacy of new cardioprotective approaches in humans (Reinstadler et al., 2017). Moreover, in the clinical scenario, IPC is not so 
feasible to investigate. For example, pre-infarct angina has been studied as an endogenous IPC stimulus and has generally associated 
with better clinical outcomes in non-diabetic patients. However, in patients with diabetes, this beneficial effect was not observed 
(Ishihara et al., 2001). Diabetes-induced impairment of IPC protection in human hearts has also been indicated by studies in which 
myocardial damage was assessed during percutaneous coronary revascularisation (Lee & Chou, 2003) and during the warm-up 
phenomenon elicited by a treadmill exercise test (Ovünç, 2000). Moreover, preconditioning protected trabeculae from non-diabetic 
patients but not trabeculae from diabetic patients (Hassouna et al., 2006; Sivaraman, Hausenloy, Wynne, & Yellon, 2010). The limited 
possibilities to study IPC in humans and the fact that patients with diabetes are increasingly well controlled by drugs make it more 
challenging to study the influences of diabetes on IPC cardioprotection. Nevertheless, it is likely that also in humans, an elevation of 
preconditioning threshold occurs (Sivaraman et al., 2010). This has been confirmed in IPC studies in other tissues and organs in which 
contradictory results are obtained in diabetic conditions (Altintas, Ozgen Altintas, Kumas, & Asil, 2019; Thomaz Neto et al., 2013). In 
many of these studies, only an augmented preconditioning protocol achieves protection. 
Dysfunctions in sarcolemmal and mitochondrial KATP channels (del Valle et al., 2003; Kersten et al., 2001) as well as glycogen synthase 
kinase-3β down-regulation (Yadav, Singh, & Sharma, 2010) have been proposed as possible mechanisms mediating diabetic attenuation 
of the protective effect of IPC. Nevertheless, to protect the diabetic myocardium, it appears necessary to increase the IPC stimulus to 
achieve a critical level of Akt phosphorylation to confer protection (Tsang et al., 2005; Figure 3). Glimepiride, an activator of Akt, may 
lower the threshold for IPC. Thus, both 1 and 3 cycles of IPC (5/10 min of ischaemia/reperfusion) may induce a cardioprotective effect in 
diabetic rat hearts treated with glimepiride (Hausenloy, Wynne, et al., 2013). 
In summary, in experimental animal and human ex vivo heart tissue studies, the presence of hyperglycaemia and diabetes mellitus 
appears to attenuate the cardioprotective efficacy of IPC and this appears to be mediated by interference with signalling pathways 
underlying IPC. However, the confounding effects of hyperglycaemia and diabetes mellitus on cardioprotection can be overcome by 
increasing the IPC stimulus. Evidence for this phenomenon are lacking in clinical studies. The disadvantage of IPC as a cardioprotective 
strategy is that it needs to be applied prior to the index ischaemic event, which is not possible to predict in the setting of acute 
myocardial infarction as such, IPost, which is applied at the onset of reperfusion, may be more effective in the setting of acute 
myocardial infarction. 
 
5 | EFFECTS OF HYPERGLYCAEMIA AND 
DIABETES ON ISCHAEMIC 
POSTCONDITIONING (IPost) 
Since IPost can be applied at the onset of reperfusion, it can be easily applied to acute myocardial infarction at the time of percutaneous 
coronary intervention (PPCI) through the inflation and deflation of the angioplasty balloon (Staat et al., 2005). The cardioprotective effect 
of IPost has been confirmed in several different animal models using varying protocols according to gender, age, species, number of 
cycles and duration of ischaemia/reperfusion, precluding the possibility of defining a single IPost algorithm (for review, see Pagliaro, 
Moro, Tullio, Perrelli, & Penna, 2011; Skyschally et al., 2009). IPost has been reported to confer cardioprotection via the production of 
several different autacoids (such as bradykinin, adenosine and opioids), which recruit known cardioprotective signalling pathways (such 
as the SAFE, NO/PKG and RISK cascades) and which converge on the mitochondrial permeability transition pore (Bell et al., 2016; 
Boengler, Heusch, & Schulz, 2011; Cohen & Downey, 2011; Lacerda, Opie, & Lecour, 2012; Oosterlinck et al., 2013; Pagliaro et al., 2011; 
Pagliaro & Penna, 2015; Penna et al., 2015). 
The clinical studies of IPost in ST-elevation myocardial infarction (STEMI) patients have mixed results with IPost limiting MI size (assessed 
by cardiac biomarkers and cardiac MRI) in most (Staat et al., 2015; Thibault, Piot, & Ovize, 2007; Xue et al., 2010) but not all studies 
(Freixa et al., 2012; Hahn et al., 2013; Sörensson et al., 2010). In addition, the DANAMI-3 study failed to demonstrate a beneficial effect of 
IPost on clinical outcomes in STEMI patients treated by percutaneous coronary intervention, although the study was underpowered 
given the lower than expected event rate (Lønborg et al., 2017). The reasons for lack of efficacy of IPost in these studies are not clear but 
have been attributed to prior preconditioning by preinfarct angina, lack of direct stenting, the presence of co-morbidities (such as 
diabetes) and co-medications (such as platelet P2Y12 inhibitors). Here, we will focus on the experimental data reporting the effect T3 of 
diabetes on the cardioprotective efficacy of IPost (Table 3). A number of experimental studies have demonstrated that the 
cardioprotective effects of IPost are blunted in both type 1 diabetes mellitus and type 2 diabetes mellitus animal models (Drenger et 
al.,2011; Przyklenk, Maynard, Greiner, & Whittaker, 2011; Ren, Song, Lu, & Chen, 2011). Also, in an in vitro cell study, it was found that 
hyperglycaemia blunted IPost-induced protection (Chen et al., 2016). Przyklenk et al. (2011) found that IPost was ineffective in type 1 
diabetes mellitus and type 2 diabetes mellitus murine models and cardioprotection was restored in the presence of insulin treatment. 
However, this finding was in contrast with anaesthetic-induced postconditioning protection, where insulin treatment failed to restore 
cardioprotection in diabetic animals (Drenger et al., 2011). This was attributed to marked inhibition of the SAFE (JAK–STAT3) and 
RISK(PI3K/Akt/eNOS) signalling cascades in the presence of diabetes (Drenger et al., 2011; Raphael, Gozal, Navot, & Zuo, 2015; Figure 3). 
It has been suggested that PTEN/Akt signalling is altered in the presence of diabetes (Mocanu & Yellon, 2007; Xue et al., 2016). It has 
been reported that the diabetic heart may be refractory to protection by Jak2-activating ligands because of angiotensin II type 1-
mediated up-regulation of calcineurin activity, however it is not clear how calcineurin activity interferes with protection by Jak2 (Hotta et 
al., 2010). Recently, also in a hyperglycaemic experimental model, a reduced level of Akt phosphorylation has been observed, a condition 
that has been associated with the loss of the cardioprotective effects of insulin in the isolated rat heart (Nakadate et al., 2017). Moreover, 
increased susceptibility to acute myocardial ischaemia–reperfusion injury in the aged, diabetic heart has been shown to be a 
consequence of impaired RISK signalling due to chronic Akt phosphorylation (Whittington et al., 2013). In the leptin receptor-deficient 
db/db mice model of type 2 diabetes mellitus, the failure of IPost to confer cardioprotection was attributed to the dysregulation of 
proteins involved with the production of cellular ATP (such as F1-ATPase [γ and Echs1]) and heat shock proteins (Zhu, Xi, & Kukreja, 
2012). In summary, the presence of hyperglycaemia/diabetes appears to blunt IPost via the down-regulation of known cardioprotective 
signalling pathways (such as SAFE and RISK) and the addition of pharmacological postconditioning agents can restore cardioprotection. 
 
 
6 | EFFECTS OF HYPERGLYCAEMIA AND DIABETES ON REMOTE ISCHAEMIC CONDITIONING (RIC) 
 
The major disadvantage of both IPC and IPost is that they require the intervention to be applied directly to the heart, thereby 
hamperingtheir clinical translation to acute myocardial infarction patients. Therefore, the phenomenon of RIC, in which the conditioning 
episodes of ischaemia and reperfusion are applied to an organ or tissue away from the heart, has greater therapeutic potential in the 
clinical setting (Cabrera-Fuentes et al., 2016; Giannopoulos et al., 2017; Pickard et al., 2015). RIC has further advantages including the 
ability to confer systemic protection against acute ischaemia–reperfusion injury in other non-cardiac organs or tissues and the ability to 
confer protection when applied either prior to, during, or at the end of the index ischaemic event, further aiding its clinical translation. 
The discovery that the RIC stimulus can be applied to the limb by simply restricting and restoring blood flow using either a tourniquet or 
pneumatic cuff to induce intermittent limb ischaemia and reperfusion has greatly facilitated the translation of RIC into the clinical 
setting. Limb RIC has been shown to reduce peri-operative myocardial injury in patients undergoing cardiac bypass surgery, but it failed 
to improve clinical outcomes in this setting (ERICCA/RIPHeart). In STEMI patients, limb RIC applied in the ambulance or on arrival at the 
hospital prior to percutaneous coronary intervention has been reported to improve myocardial salvage and/or reduce MI size 
(Hausenloy et al., 2015). However, the recently published large multicentre 5,401 STEMI patients CONDI2/-ERIC-PPCI trial failed to show 
any clinical benefit of limb RIC, with no differences in rates of cardiac death or hospitalisation for heart failure (HF) when compared with 
control, regardless of diabetes present in 11.9% of patients subjected to RIC (Hausenloy et al., 2019). 
The reasons for the neutral results of limb RIC in the clinical setting are not clear but could relate to the presence of co-morbidities (such 
as age or diabetes mellitus) and co-medications (such as P2Y12 platelet inhibitors) acting as confounders of cardioprotection. In this 
regard, experimental studies have shown that acute hyperglycaemia was able to abrogate cardioprotection elicited by limb RIC in a rat 
acute myocardial infarction model. This effect was associated with increased incidence and duration of arrhythmias and an increase in 
nitrosative stress and activation of the mTOR pathway (Baranyai et al., 2015). In the clinical setting, evidence for hyperglycaemia or 
diabetes interfering with RIC cardioprotection is lacking, although clinical studies in CABG and STEMI patients have reported 
cardioprotection with RIC despite including 20% diabetic patients (Eitel et al., 2015). 
Interestingly, Kottenberg et al. (2014) have reported that cardioprotection by RIC was abrogated in sulphonylurea-treated diabetic 
patients undergoing cardiac surgery, data that are consistent with this agent antagonising the ATP-dependant potassium channel, which 
is known to mediate cardioprotection. Recently, a review by Tyagi, Singh, Virdi, and Jaggi (2019) summarised the possible mechanisms 
that can explain how diabetes abolishes cardioprotective effects of RIC. It has been reported that protection conferred by RIC may 
involve the attenuation of the sympathetic nervous system response to ischaemia, in healthy humans (Lambert et al., 2016). We can 
speculate that the inefficacy of RIC in diabetes may also be in part explained by the autonomic dysfunction that is getting worse in type 
2 diabetes mellitus patients (Istenes et al., 2014). Indeed, the metaboreflex (the reflex response stimulated by metabolite accumulation 
during limb exercise and/or ischaemia) is abnormal in type 2 diabetes mellitus patients and it is characterised by an exaggerated 
vasoconstriction (perhaps due to sympathetic overstimulation) not accompanied by a concomitant increase in heart performance 
(Roberto et al., 2019). This speculation is in line with a study, where the plasma dialysate collected from patients with diabetes after RIC 
triggered cardioprotection only in the absence of diabetic neuropathy of the upper limbs (Jensen, Støttrup, Kristiansen, & Bøtker, 2012). 
However, additional studies are necessary (especially multicentric randomised clinical trial in patients with acute myocardial infarction for 
RIC with clinical outcome as the primary endpoint) to understand the role of hyperglycaemic and diabetes on the loss of 
cardioprotective effects by RIC and whether combined approaches (e.g. RIC plus IPost) may be necessary to overcome the protective 
blinding induced by diabetes in post-acute myocardial infarction patients. 
In summary, there is initial experimental evidence that acute hyperglycaemia blunts limb RIC cardioprotection, but evidence in the 
clinical setting is lacking. Therefore, further large clinical cardioprotection studies are needed to determine whether diabetes mellitus is 
actually a confounder of limb RIC cardioprotection. 
 
 
7 | EFFECTS OF ANTI-HYPERGLYCAEMIC MEDICATIONS ON ACUTE MYOCARDIAL ISCHAEMIA–
REPERFUSION INJURY AND CARDIOPROTECTION 
The majority of diabetic patients are on anti-hyperglycaemic medications to control their blood glucose levels, and there is experimental 
and clinical data suggesting that these medications can themselves either confer cardioprotection or interfere with cardioprotection 
elicited by IPC, IPost and RIC. It must be noted that some of these anti-hyperglycaemic agents confer cardiovascular protection that may 
be unrelated to cardioprotection against acute myocardial ischaemia–reperfusion injury. These issues make it challenging to determine 
whether the presence of diabetes actually confounds cardioprotection in clinical studies. In this section, we provide an overview 
highlighting the effects of older and newer antihyperglycaemic medications on acute myocardial ischaemia–reperfusion injury and 
cardioprotection. 
7.1 | Sulphonylureas 
This class of anti-hyperglycaemic agents act by binding to a subunit of the β-cell KATP channel complex, leading to the closure of the 
channel, thus stimulating/potentiating insulin secretion and lowering blood glucose levels (Brunton, Lazo, & Parker, 2006). By also 
binding to cardiac KATP channels, sulphonylureas such as glibenclamide have been shown in experimental studies to interfere with IPC 
cardioprotection, since KATP channel opening has been shown to contribute to IPC cardioprotection (Ye et al., 2011). It appears that the 
newer sulphonylureas such as glimepiride (Mocanu et al., 2001) and gliclazide (Maddock, Siedlecka, & Yellon, 2004) do not interfere 
with IPC cardioprotection, and this is possibly related to their greater specificity for pancreatic compared with myocardial KATP channels 
(Gribble & Ashcroft, 1999). In the clinical setting, diabetic patients undergoing cardiac bypass surgery who were on treatment with 
sulphonylureas were not protected by RIC (Kottenberg et al., 2014) and in another study, glibenclamide was shown to abolish 
endothelial protection induced by RIC (Loukogeorgakis et al., 2007). 
 
7.2 | Metformin 
This agent is a biguanide whose effects are mediated by the activation of the AMP-activated protein kinase and lowers blood glucose 
levels by reducing liver production of glucose and increasing insulin sensitivity (Cho et al., 2015). There is extensive experimental animal 
data showing that treatment with metformin either prior to ischaemia or at onset of reperfusion can reduce MI size (reviewed in Ye et al., 
2011). The mechanisms underlying metformin cardioprotection are diverse and include activation of adenosine receptors, recruitment of 
the RISK pathway, AMP-activated protein kinase activation, modulation of complex I and inhibition of mitochondrial permeability 
transition pore opening at reperfusion (Bromage & Yellon, 2015; Mohsin et al., 2019). In the clinical setting, most meta-analyses have 
supported the cardiovascular safety of metformin and have shown it to reduce the risk of re-infarction and all-cause mortality in the 
long term in patients with coronary artery disease and chronic heart failure, independent of its glucoselowering effects (Varjabedian, 
Bourji, Pourafkari, & Nader, 2018). However, no acute protection by metformin administration during CABG was observed (El Messaoudi 
et al., 2015), questioning the translatability of metformin for protection against acute I/R conditions in the clinical setting.  
 
7.3 | Thiazolidinediones 
These agents act as selective agonists for nuclear PPAR-γ and lower blood glucose levels by reducing insulin resistance. Experimental 
animal studies have reported cardioprotection with these agents administered either prior to ischaemia and at onset of reperfusion (Ye 
et al., 2008; Zhang et al., 2010), with potential mechanisms including decreased expression of microRNA-29a and 29c (Ye, Hu, Lin, Zhang, 
& Perez-Polo, 2010), activation of the RISK pathway (Wynne, Mocanu, & Yellon, 2005) and alternative pathways including Src family 
kinase- and MMP-dependent transactivation of EGF and PDGF receptors (Ichiki et al., 2004). Clinical studies and a meta-analysis have 
suggested that pioglitazone reduces cardiovascular complications in patients with type 2 diabetes mellitus (Nissen et al., 2008), whereas 
in contrast, rosiglitazone has been associated with worsened adverse cardiovascular outcomes (Lincoff, Wolski, Nicholls, & Nissen, 
2007). 
 
7.4 | Glucagon-like peptide-1 receptor agonists 
This class of anti-hyperglycaemic agents lower blood glucose levels by an insulin incretin effect (Peng, Want, & Aroda, 2016). Several 
studies have shown that GLP-1 or GLP-1 analogues administered as either preconditioning or postconditioning agents limit MI size in 
small animal models (Matsubara et al., 2009; Sonne, Engstrom, & Treiman, 2008). However, studies in pigs have shown divergent results: 
GLP-1 and liraglutide do not limit infarct size (Kavianipour et al., 2003; Kristensen et al., 2009), whereas exenatide reduces infarct size 
(Timmers et al., 2009). Proposed mechanisms of actions include activation of the GLP receptor, PKA and RISK pathways, and eNOS 
phosphorylation. Indeed, the mechanisms through which the cardioprotection occurs is not fully defined but may include activation of 
the subcellular pathways of IPC and modulation of myocardial metabolism (reviewed in Giblett et al., 2016). Glucagonlike peptide-1 
receptor agonist therapy can also modulate innate immune-mediated inflammation (Hogan et al., 2014). Limited data suggest that GLP-
1 receptor agonists may be effective for the treatment of cardiac disorders in patients with and without diabetes mellitus. These studies 
suggest that GLP-1 receptor agonists may have potential pleiotropic beneficial effects in patients with cardiovascular disease beyond 
their role in managing diabetes. These medications may be cardioprotective after an acute myocardial infarction but are less promising 
in heart failure (Marso et al., 2016; reviewed in Wroge & Williams, 2016). 
 
7.5 | Dipeptidyl peptidase-4 inhibitors 
This is a new class of drugs for treating type 2 diabetes mellitus lowering blood glucose levels by augmenting endogenous levels of GLP-
1 through the inhibition of dipeptidyl peptidase-4 (DPP-4; Pauly et al., 1996). Experimental studies in small animals and in pigs have 
shown that sitagliptin and vildagliptin limited MI size when they were administered before ischaemia or at reperfusion (Hausenloy, 
Whittington, et al., 2013; Theiss, Gross, & Vallaster, 2013). The mechanism of action includes augmentation of the effects of endogenous 
incretins and activation of the GLP-1 receptor leading to generation of cAMP with downstream activation of PKA (reviewed in Yoon, Ye, 
& Birnbaum, 2014). Clinical trials evaluating the overall cardiovascular risks and benefits after administration of dipeptidyl peptidase-4 
inhibitors have shown that hospitalisation for heart failure was increased in saxagliptin-treated patients (Scirica et al., 2013), whereas the 
rates of major adverse cardiovascular events were not increased with the alogliptin and sitagliptin as compared with placebo (Green et 
al., 2015; White et al., 2013). Nevertheless, the relationship between dipeptidyl peptidase-4 inhibitors and heart failure is complex 
(reviewed in Ziff, Bromage, Yellon, & Davidson, 2018). 
 
7.6 | Sodium–glucose co-transporter 2 inhibitors 
This new class of approved anti-hyperglycaemic agents lower blood glucose by inhibiting glucose reabsorption in the kidney (Majewski 
& Bakris, 2015; Wanner et al., 2016). Recently published landmark cardiovascular outcome trials (EMPA-REG OUTCOME, Fitchett et al., 
2016; CANVAS, Neal et al., 2017; and DECLARETIMI 58 trial, Wiviott et al., 2019) have shown that the sodium– glucose co-transporter 2 
(SGLT2) inhibitors (empagliflozin, canagliflozin and dapagliflozin) reduced rates of cardiovascular death and hospitalisation for heart 
failure in type 2 diabetes mellitus patients at risk of cardiovascular disease. However, the mechanisms underlying these protective 
cardiovascular effects remain unclear. 
Experimental studies have investigated whether SGLT2 inhibitors are able to exert cardioprotective effects against acute myocardial 
ischaemia–reperfusion injury. Chronic therapy with empagliflozin (Andreadou et al., 2017), canagliflozin (Lim et al.,  2019, or dapagliflozin 
(Tanajak et al., 2018) have been reported to reduce MI size in both diabetes mellitus and non-diabetes mellitus rodent models of acute 
myocardial ischaemia–reperfusion injury. The cardioprotective mechanisms have been attributed to a variety of factors including 
increased STAT3 phosphorylation, reduced myocardial IL-6 and inducible NOS expression, inhibition of mitochondrial fission, 
preservation of mitochondrial function and regulation of redox signalling in the ischaemic myocardium (Andreadou et al., 2017; Mizuno 
et al., 2018; Ng et al., 2018; Tanajak et al., 2018). However, acute administration of SGLT2 inhibitors failed to reduce MI size in the 
isolated mouse/rat heart, suggesting that the infarct size-reducing effects of SGLT2 inhibitors may require longterm treatment (Lim et al., 
2019; Uthman et al., 2019). However, SGLT2 inhibitors have shown acute functional protective effects, improving cardiac performance 
during ischaemia (Baker et al., 2019; Uthman et al., 2019). This may suggest that some of the beneficial effects of SGLT2 inhibitors are 
acutely and directly on the myocardium, despite the fact that SGLT2 is mainly expressed in the kidney and only minimally in the heart. In 
this regard, interesting studies have suggested that the SGLT2 inhibitors may have off-target inhibitory effects on the cardiac sodium 
hydrogen exchanger, which would be expected to prevent sodium and calcium overload and may in part explain their cardioprotective 
effects (Uthman et al., 2018, 2019). 
Whether the observed cardioprotective effects of chronic SGLT2 inhibitor therapy can explain the cardiovascular outcome benefits 
observed in the large clinical outcomes studies is not known, and other benefits on cardiac metabolism, cardiac hypertrophy and heart 
function have been proposed (Baker et al., 2019; García-Ropero, Vargas-Delgado, Santos-Gallego, & Badimon, 2019; Habibi et al., 2017; 
Oshima et al., 2019; Santos-Gallego et al., 2019; Verma et al., 2019; Xue et al., 2019; Yurista et al., 2019). 
In summary, investigating the confounding effects of antihyperglycaemic agents on cardioprotective strategies such as IPC, IPost and 
RIC is challenging given that many of these therapies (such as metformin, thiazolidinediones, GLP-1 agonists, dipeptidyl peptidase-4 
inhibitors and SGLT2 inhibitors) appear to exert cardioprotective effects against acute ischaemia–reperfusion injury in experimental 
animal studies. However, whether these cardioprotective effects can explain their beneficial effects on cardiovascular outcomes in 
diabetic patients is not clear. Further studies are needed to determine the mechanisms underlying the cardioprotective effects of the 
newer anti-hyperglycaemic agents such as GLP-1 agonists, dipeptidyl peptidase-4 inhibitors, and SGLT2 inhibitors. 
 
 
8 | SUMMARY AND CONCLUSIONS 
In summary, there are convincing data that hyperglycaemia and diabetes may attenuate the cardioprotective effects of IPC, Ipost and 
RIC, but whether this is true in the clinical setting has not been demonstrated (Kleinbongard, Bøtker, Ovize, Hausenloy, & Heusch, 2019). 
At least in the experimental setting, a stronger “conditioning” stimulus or use of certain drugs can target hyperglycaemia/diabetes 
mellitus-induced down-regulated signalling pathways, in order to restore cardioprotection. The picture is further complicated by the 
heterogeneity of animal models used and this may explain some of the diverse results reported. Further experimental studies are needed 
to elucidate the potential mechanisms underlying the confounding effects of hyperglycaemia/diabetes mellitus on endogenous 
cardioprotection. Importantly, additional clinical studies are needed to confirm whether the confounding effects of 
hyperglycaemia/diabetes mellitus on endogenous cardioprotection are replicated in diabetic patients. The latter is difficult to investigate 
given that most diabetes mellitus patients are on anti-hyperglycaemic agents (such as GLP-1 agonists, dipeptidyl peptidase-4 inhibitors 
and SGLT2 inhibitors), which in themselves are known to be cardioprotective. Importantly, novel cardioprotective strategies for inducing 
ischaemia tolerance and to reduce ischaemia–reperfusion injury in patients with diabetes are needed to improve clinical outcomes in this 
high-risk group. 
 
8.1 | Nomenclature of targets and ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the 
common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Q31 
Concise Guide to PHARMACOLOGY 2019/20 (Alexander, Fabbro, et al., 2019; Alexander, Kelly, et al., 2019). 
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Figure 1: Schematic representation of the various protocols of ischaemic conditioning. White 
boxes represent time of normal perfusion or reperfusion; dark blue boxes are periods of 




Figure 2: Schematic summary of 130 studies reporting effects on cardiac sensitivity to IRI of 
acute hyperglycaemia (A, B), early type 1 Diabetes Mellitus (C, D), late type 1 Diabetes 
Mellitus (E, F) and Type 2 Diabetes Mellitus (G, H) for the isolated heart (A, C, E and G) or 
the in vivo condition (B, D, F and H), respectively. Within each of the 8 categories, to obtain 
the percentage, the number of studies reporting increased IS (IIS), neutral (N) or decreased 
IS (DIS) is divided by the total number of studies in that category. The following references 
were used (given by their PubMed Identifier number, PMID):  
A (IIS: 24286628, 12189448, 20206553; N: 20206553, 24908083; DIS: 26491698);  
B (IIS: 30596897, 9683464, 10749717, 29506687, 29169909, 17519283, 26014921, 
24371503, 27753144; N: 20124983, 23666677, 26581389, 26359322, 12739155, 
18362595, 30596897, 18305078, 22436066, 25446919, 11753019, 9683464, 11247788, 
22239823, 20125034, 25812079, 18655783, 24845581; DIS: none);  
C (IIS: none; N: 20578962; DIS: 30682388, 26674282, 27418904);  
D (IIS: 27217295, 28500760, 24286628, 12189448, 15331549, 15054118; N: 24466263, 
23922853, 22881281, 17192474; DIS: 22347376, 16955284, 12956412 ); 
E (IIS: 26487889, 23262803, 29035826, 22948709, 17664136 N: 22826102, 26504753, 
20981553, 26423303, 10615421, 25436201, 21182845, 23262803, 20950993 DIS: none);  
F (IIS: 8287395, 26973173, 24923878, 23777472, 24041262, 28851567, 15734856, 
22829582, 24303086, 28038474, 29062465, 29605032, 29477090, 29533954, 30797815, 
28714516, 28765969; N: 23342967, 21368653, 12739155, 10749717, 11247788, 
25140754, 24041262, 26783539, 16955284, 12148084, 23591995, 12956412, 22482760, 
28183205, 3359580, 14738870; DIS: 17505800, 9769241, 14738870); 
G (IIS: 27398138, 25911189, 23106693, 2338503, 29121919; N: 18080084, 28335529, 
20578962, 26582369, 16046302; DIS: 15480537). H (IIS: 26763290, 18689499, 18083782, 
26489513, 25068621, 29474385, 18436235, 19910577, 14534360, 17008456, 18178726, 
19755525, 23201226, 29912977, 22853195, 23432808, 30062222, 15677515, 26885264; 
N: 19151258, 19244549, 19597978, 24346177, 23507122, 26861496, 29524006, 






Figure 3: Mechanisms of loss of conditioning protection in diabetic hearts. In the early stages of 
diabetes, the heart is in a paradoxical state of protection. Subsequently, diabetic hearts may have 
an increased threshold for conditioning protection, the reasons for which are multifactorial. These 
include downregulation and alteration of the prosurvival kinase pathways, dysregulation of the 
mPTP, dysfunction of the mitochondrial KATP channel in the mitochondria and increased calcineurin 





Table 1: Brief overview of the most frequently used rodent models of diabetes mellitus 






































































(Mering JV, 1889)  






• Useful for pancreatic regeneration studies. 
• Can be used in all animal model species. 
• Avoids pharmacologic toxicity of DM-induction drugs. 
• Similar to type-2 DM due to pancreatic degeneration. 
Alloxan 
(mouse, rat) 
(Rerup, 1970)  
Phar 1         • Significant 
hyperglycaemia. 






• Neuropathy and 
cardiomyopathy. 




(Rakieten et al., 
1963)  




• Muscular atrophy. 
• Neuropathy. 
• Fast, economic and consistent. 
 




(Kawano et al., 
1992)  
 
Gen 2             • Polyuria, 
polydipsia. 








• Good model to test antidiabetic and anti-hypertensive drugs. 
• Progressive DM: 
1. Prediabetic phase (0-9 wks): pancreatic islet hyperplasia and 
lymphocytes’ infiltration. 
2. Type-2 DM phase: Intermediate phase (10-40 wks): pancreatic islet 
fibrosis. 
3. Type-1 DM: (>40 wks): pancreatic islet atrophy.  
ZDF - Zucker 
Diabetic Fatty 
Rat 
(Janssen et al., 
1999)  
Gen 2             • Dysfunctional 
leptin receptor. 
• Hyperphagia. 
• 25-55% decreased 
GLUT4 expression. 








• Widely used. 
• Mild hyperglycaemia (similar to humans) 
• Good model to test insulin-resistance, insulin sensitizers or insulinotropic 
drugs. 
• ZDF were selectively bred from Zucker fatty rat which are similar but 
without hyperglycaemia. 






















































































• Liver steatosis 
(~20 wks) without 
steatohepatitis. 
• ♀ ZSF X ♂ SHHF 
rats. 
• Widely used. 
• Robust animal model heart failure with preserved ejection fraction. 
Goto-kakizaki 
Rat 
(Goto et al., 
1988)  








an early stage of 
life. 
• Stable degree of glucose intolerance.  
• Useful for studying advanced diabetic nephropathy. 
• Wistar rats are the control group. 
Wistar Fatty  
Rat 









• WKY x Zucker 
selective 
breeding. 
• Wistar rats are the control group. 
Db/db or Leprdb 
Mice 
(Chen et al., 
1996)  












• Increased LV 
mass, fatty acid 
oxidation and 
RAAS activation. 
• Advantages associated with mice reduced size. 
increase until the 16th week. 
Ob/ob or Lepob 
Mice 
(Ingalls et al., 
1950)  
Gen 2            • Leptin deficiency. 
• Hyperphagia and 




(15 wks, following 
obesity). 




• Advantages associated with mice reduced size. 
• Allows the evaluation of the early effects of obesity and insulin resistance 
on cardiac function and the effects of additional hyperglycaemia at older 
ages. 
• Good model to test anti-obesity treatments. 
homeostasis and 
cardiac efficiency. 
• Increased LV 
mass, fatty acid 
oxidation and lipid 
content. 




































































High fat diet 
C57BL/6J 
Mice 
(Surwit et al.,  
1995)  
Diet 2           • Leptin and insulin 
resistance. 







• Advantages associated with mice reduced size. 
• Present many genetic and environmental features of the human disease.  
• High fat diet C57BL/6J mice changes myocardial substrate utilization prior 
to obesity and severe insulin resistance. 
• Useful for pharmacologic tests. 







(Levin et al., 
1997)  
Diet 2           • Hyperleptinaemia. • Similar to the onset of type-2 DM in humans 
Animal models are subdivided into 4 types: surgical (Surg), pharmacological (Phar), genetic (Gen) and diet models. LV, left ventricle; 




Table 2 – Ischaemic and Pharmacological Preconditioning in Diabetic 









     Ischaemic Preconditioning (IPC) 
Acute hyperglycaemia 
Mice: C57BL/6. (Acute 
hyperglycaemia induced by 
i.p. 20% dextrose 50 mins 
prior to LAD occlusion) 
Ex vivo, 40 min 
ischaemia/1 hr 
reperfusion 
2 cycles of 5 min 
ischaemia/ 5 min 
reperfusion 
Acute hyperglycaemia 




Rats: Male Wistar - 
(Hyperglycaemia induced by 
22 mmol/l, ex vivo) 
 
Ex vivo, 30 min 
ischaemia/2 hr 
reperfusion 
2 cycles of 5 min 
ischaemia/ 5 min 
reperfusion 
Acute hyperglycaemia did not 





Rats: STZ, 50 mg/kg i.p 
 
Ex vivo, 30 min 
ischaemia/2 hr 
reperfusion 
(6 wks after STZ) 
2 cycles of 5 min 
ischaemia/5 min 
reperfusion 
IPC was attenuated but was 
restored by zinc chloride and 
zinc ionophore pyrithione  
26423303 
T1DM 
Rats: Male Sprague-Dawley; 
STZ, 70 mg/kg 
In vivo, 30 min  
ischaemia/3 hr 
reperfusion 
(7 days after STZ) 




T1DM did not affect IRI but 
IPC was abrogated 
Exogenous insulin 




Rats: Male Zucker diabetic 
fatty rats (homozygote 
(fa/fa)) at ages 6-
(prediabetic), 12- (early 
TD2M) and 24-weeks of age 
(Late T2DM) 
Ex vivo, 40 min 
ischaemia/2 hr 
reperfusion. 
2 cycles of 5 min 
ischaemia/5 min 
reperfusion 
T2DM increased vulnerability 
to IRI  but the cardioprotective 
effect of IPC was preserved in 
in pre-diabetic, early and late 




sensitive (CDs) rats fed high-
sucrose/low-copper diet 
(HSD) 
Ex vivo, 35 min 
ischaemia/2 hr 
reperfusion 
3 cycles of 2 min 
ischaemia/3 min 
reperfusion 





Rats: Diabetic Goto-Kakizaki 
rats, 3, 8, 12, or 18 months 
of age 
Ex vivo, 35 min 
ischaemia/2 hr 
reperfusion 
3 cycles of 5 min 
ischaemia/10 min 
reperfusion  
T2DM was associated with 
increased susceptibility to IRI 
in the aged, diabetic heart and 
IPC was attenuated 
23723063 
T2DM 
Rats: Diabetic ZDF (fa/fa) 
and non-diabetic (fa/+)  




(Hypo; glucose 3 
mmol/l) 




IPC was effective in both 
diabetic and non-diabetic 
hearts. Hypoglycaemia 
worsened IRI in both models 
and IPC in non-diabetic only. 
29121919 
T2DM 
Rats: Goto-Kakizaki rats 
(type II lean model of 
diabetes) 
Ex vivo, 35 min 
ischaemia/2 hr 
reperfusion 
1 or 3 cycles of 5 
min ischaemia/10 
min reperfusion;  
3-IPC cycles were required for 
cardioprotection in T2DM. Pre-
treatment with glimepiride 
lowered the threshold for IPC 
and both 1 and 3 cycles of IPC 
limited IRI. 
2326338 
Pharmacological Preconditioning (PPC) 
Acute hyperglycaemia 
Rats: Male Wistar,  
Infusion of modified Krebs–
Henseleit (600 mg/dL 
glucose) 
Ex vivo, 15 min 
ischaemia/20 min 
reperfusion 
Insulin (0.5 U/L) Acute hyperglycaemia blunts 
the cardioprotective effects of 
pre-ischemic insulin PPC 
28376800 
T1DM 
Rats: Sprague-Dawley,  
Diabetes injected with 1% 
streptozotocin (55 mg/kg) 
In vivo 30 min 
ischaemia/4 hr 
reperfusion  





once a day for 7 
days. 




Rat: Wistar either sex, a 
single dose of alloxan 
monohydrate (120 mg/kg) 
Ex vivo, 30-min 
ischaemia/2 hr 
reperfusion  
(5 wks after 
alloxan) 
Atrial natriuretic 
peptide (ANP) 0.1 
μM/L 




Rats: Wistar male. STZ 
injection at the age of 4 week 
(35 mg/kg, i.p).  
Ex vivo, 30 min  
ischaemia/1 hr 
reperfusion 
(3 mos after STZ) 
NaHS (20 μM) for 
15 min prior to I/R  





Rats: Wistar, STZ (35 
mg/kg, i.p., once) and 
feeding a high fat diet (HFD) 
for 6 weeks 







ischaemia for 20 
min 
PPC by S1P agonist FTY720 
reduces IRI in T2DM 
26582369 
T2DM 
Mice: Male nondiabetic 
(C57BLKS/J) and diabetic 
(BKS.Cg-ock7M+/+Leprdb/J 
mice; 
In vivo, 30 min 
ischaemia/ 2 h of 
reperfusion 
Na2S either 24 hr 
before ischaemia or 
as a daily injection 
for 7 days 
Na2S PPC attenuates 
myocardial IRI in T2DM 
23479260 
Abbreviations: KH, Krebs–Henseleit; LAD, left anterior descending artery; PMID, PubMed identifier number; 
STZ, streptozotocin; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus. 
 
 
 
